News Releases

Keyword Search

Oct-22-2024
Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Sep-12-2024
Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives
Aug-08-2024
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
Aug-01-2024
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results
Jul-15-2024
Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Jul-11-2024
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
May-30-2024
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
May-09-2024
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
May-02-2024
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results
May-01-2024
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)